<DOC>
	<DOCNO>NCT01557127</DOCNO>
	<brief_summary>This study registry renal cancer patient treat Nexavar . It aim evaluate actual dosing Nexavar `` real-life '' set vs. prescribe dose .</brief_summary>
	<brief_title>Nexavar Dosing Renal Cancer Patients `` Real-life '' Setting</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>Age &gt; /= 18 year Diagnosis renal cell carcinoma Failure prior therapy interferonalfa ( IFN ) interleukine2 ( IL2 ) disqualify therapy IFN/IL2 Patients oncologist decide start therapy sorafenib . Synonymous contraindication Nexavar .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Renal cell carcinoma ,</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Dosing</keyword>
</DOC>